Blood Reviews
Volume 23, Issue 6 , Pages 267-274 , November 2009

Prophylactic therapy in haemophilia

  • Rolf Ljung

      Affiliations

    • Corresponding Author InformationTel.: +46 40 33 00 00; fax: +46 40 33 62 26.

References 

  1. Ramgren O. Haemophilia in Sweden. III. Symptomatology, with special reference to differences between haemophilia A and B. Acta Med Scand. 1962;171:237–242
  2. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of haemophilia A and B. Acta Orthop Scand Suppl. 1965;(Suppl 77):3–132
  3. Chambost H, Ljung R. Changing pattern of care of boys with haemophilia in western European centres. Haemophilia. 2005;11:92–99
  4. Donadel-Claeyssens S. Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia. 2006;12:124–127
  5. Ota S, McLimont M, Carcao MD, Blanchette VS, Graham N, Paradis E, et al. Definitions for haemophilia prophylaxis and its outcomes: the Canadian consensus study. Haemophilia. 2007;13:12–20
  6. Geraghty S, Dunkley T, Harrington C, Lindvall K, Maahs J, Sek J. Practice patterns in haemophilia A therapy – global progress towards optimal care. Haemophilia. 2006;12:75–81
  7. Nilsson IM, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years’ experience of prophylactic treatment in severe haemophilia A and B. J Int Med. 1992;232:25–32
  8. Nilsson IM. Management of haemophilia in Sweden. Thromb Haemost. 1976;35:510–521
  9. Blomback M, Nilsson IM. Treatment of hemophilia A with human antihemophilic globulin. Acta Med Scand. 1958;161:301–321
  10. Ljung RC. Aspects of haemophilia prophylaxis in Sweden. Haemophilia. 2002;8(Suppl 2):34–37
  11. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediatr Hematol Oncol. 1991;13:280–287
  12. van Creveld S. Prophylaxis in haemophilia. Lancet. 1971;1:450
  13. Van Creveld S. Prophylaxis of joint hemorrhages in hemophilia. Acta Haematol. 1971;45:120–127
  14. van den Berg HM, Fischer K, Mauser-Bunschoten EP, Beek FJ, Roosendaal G, van der Bom JG, et al. Long-term outcome of individualized prophylactic treatment of children with severe haemophilia. Br J Haematol. 2001;112:561–565
  15. Lofqvist T, Nilsson IM, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients – a long-term follow-up. J Int Med. 1997;241:395–400
  16. Kreuz W, Escuriola Ettingshausen C, Funk M, Pons S, Schmidt H, Kornhuber B. Prevention of joint damage in hemophilic children with early prophylaxis. Orthopade. 1999;28:341–346
  17. Aledort LM, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Int Med. 1994;236:391–399
  18. Steen Carlsson K, Hojgard S, Glomstein A, Lethagen S, Schulman S, Tengborn L, et al. On-demand vs. prophylactic treatment for severe haemophilia in Norway and Sweden: differences in treatment characteristics and outcome. Haemophilia. 2003;9:555–566
  19. Fischer K, van der Bom JG, Molho P, Negrier C, Mauser-Bunschoten EP, Roosendaal G, et al. Prophylactic versus on-demand treatment strategies for severe haemophilia: a comparison of costs and long-term outcome. Haemophilia. 2002;8:745–752
  20. Stobart K, Iorio A, Wu JK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2005: CD003429.
  21. Aledort L, Ljung R, Blanchette V. Are randomized clinical trials the only truth? Not always. J Thromb Haemost. 2006;4:503–504
  22. Manco-Johnson MJ, Abshire TC, Shapiro AD, Riske B, Hacker MR, Kilcoyne R, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357:535–544
  23. Lundin B, Ljung R, Pettersson H. MRI scores of ankle joints in children with haemophilia – comparison with clinical data. Haemophilia. 2005;11:116–122
  24. Kreuz W, Escuriola-Ettingshausen C, Funk M, Schmidt H, Kornhuber B. When should prophylactic treatment in patients with haemophilia A and B start? – The German experience. Haemophilia. 1998;4:413–417
  25. Pettersson H, Ahlberg A, Nilsson IM. A radiologic classification of hemophilic arthropathy. Clin Orthop Relat Res. 1980;153–159
  26. Soreff J, Blomback M. Arthropathy in children with severe hemophilia A. Acta Paediatr Scand. 1980;69:667–673
  27. Gringeri A. Prospective controlled studies on prophylaxis: an Italian approach. Haemophilia. 2003;9(Suppl 1):38–42[discussion 3]
  28. Fischer K, Astermark J, van der Bom JG, Ljung R, Berntorp E, Grobbee DE, et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia. 2002;8:753–760
  29. Ljung R, Aronis-Vournas S, Kurnik-Auberger K, van den Berg M, Chambost H, Claeyssens S, et al. Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries. Haemophilia. 2000;6:619–624
  30. Astermark J, Petrini P, Tengborn L, Schulman S, Ljung R, Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol. 1999;105:1109–1113
  31. Ljung R. The risk associated with indwelling catheters in children with haemophilia. Br J Haematol. 2007;138:580–586
  32. Ljung R. Paediatric care of the child with haemophilia. Haemophilia. 2002;8:178–182
  33. Petrini P. Treatment strategies in children with hemophilia. Paediatr Drugs. 2002;4:427–437
  34. Petrini P, Chambost H, Nemes L. Towards the goal of prophylaxis: experience and treatment strategies from Sweden, France and Hungary. Haemophilia. 2004;10(Suppl 4):94–96
  35. Santagostino E, Gringeri A, Berardinelli L, Beretta C, Muca-Perja M, Mannucci PM. Long-term safety and feasibility of arteriovenous fistulae as vascular accesses in children with haemophilia: a prospective study. Br J Haematol. 2003;123:502–506
  36. Feldman BM, Pai M, Rivard GE, Israels S, Poon MC, Demers C, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost. 2006;4:1228–1236
  37. Ahnstrom J, Berntorp E, Lindvall K, Bjorkman S. A 6-year follow-up of dosing, coagulation factor levels and bleedings in relation to joint status in the prophylactic treatment of haemophilia. Haemophilia. 2004;10:689–697
  38. Ljung RC. Intracranial haemorrhage in haemophilia A and B. Br J Haematol. 2008;140:378–384
  39. Stieltjes N, Calvez T, Demiguel V, Torchet MF, Briquel ME, Fressinaud E, et al. Intracranial haemorrhages in French haemophilia patients (1991–2001): clinical presentation, management and prognosis factors for death. Haemophilia. 2005;11:452–458
  40. Traivaree C, Blanchette V, Armstrong D, Floros G, Stain AM, Carcao MD. Intracranial bleeding in haemophilia beyond the neonatal period – the role of CT imaging in suspected intracranial bleeding. Haemophilia. 2007;13:552–559
  41. Antunes SV, Vicari P, Cavalheiro S, Bordin JO. Intracranial haemorrhage among a population of haemophilic patients in Brazil. Haemophilia. 2003;9:573–577
  42. Revel-Vilk S, Golomb MR, Achonu C, Stain AM, Armstrong D, Barnes MA, et al. Effect of intracranial bleeds on the health and quality of life of boys with hemophilia. J Pediatr. 2004;144:490–495
  43. Giroud M, Milan C, Beuriat P. Incidence and survival rates during a two-year period of intracerebral and subarachnoid haemorrhages, cortical infartcs, lacunes and transient ischaemic attacks. The stroke Registry of Dijon: 1985–1989. Int J Epidemiol. 2001;20:892–899
  44. Nilsson OG, Lindgren AC, Stahl N, Brandt L, Säveland H. Incidence of intracerebral and subarachnoidal haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatr. 2000;69:601–607
  45. Arnold WD, Hilgartner MW. Hemophilic arthropathy. Current concepts of pathogenesis and management. J Bone Joint Surg Am. 1977;59:287–305
  46. Nuss R, Kilcoyne R, Geraghty S, Wilkins R, Wiedel J, Manco-Johnson M. Magnetic resonance imaging visualization of hemorrhage into a suprapatellar pouch in a child with hemophilia. Am J Pediatr Hematol Oncol. 1994;16:183–185
  47. Nuss R, Kilcoyne RF, Geraghty S, Shroyer AL, Rosky JW, Mawhinney S, et al. MRI findings in haemophilic joints treated with radiosynoviorthesis with development of an MRI scale of joint damage. Haemophilia. 2000;6:162–169
  48. Nuss R, Kilcoyne RF, Geraghty S, Wiedel J, Manco-Johnson M. Utility of magnetic resonance imaging for management of hemophilic arthropathy in children. J Pediatr. 1993;123:388–392
  49. Nuss R, Kilcoyne RF, Rivard GE, Murphy J. Late clinical, plain X-ray and magnetic resonance imaging findings in haemophilic joints treated with radiosynoviorthesis. Haemophilia. 2000;6:658–663
  50. Lundin B, Babyn P, Doria AS, Kilcoyne R, Ljung R, Miller S, et al. Compatible scales for progressive and additive MRI assessments of haemophilic arthropathy. Haemophilia. 2005;11:109–115
  51. Lundin B, Pettersson H, Ljung R. A new magnetic resonance imaging scoring method for assessment of haemophilic arthropathy. Haemophilia. 2004;10:383–389
  52. Funk MB, Schmidt H, Becker S, Escuriola C, Klarmann D, Klingebiel T, et al. Modified magnetic resonance imaging score compared with orthopaedic and radiological scores for the evaluation of haemophilic arthropathy. Haemophilia. 2002;8:98–103
  53. Kilcoyne RF, Nuss R. Radiological assessment of haemophilic arthropathy with emphasis on MRI findings. Haemophilia. 2003;9(Suppl 1):57–63[discussion-4]
  54. Soler R, Lopez-Fernandez F, Rodriguez E, Marini M. Hemophilic arthropathy. A scoring system for magnetic resonance imaging. Eur Radiol. 2002;12:836–843
  55. Dobon M, Lucia JF, Aguilar C, Mayayo E, Roca M, Solano V, et al. Value of magnetic resonance imaging for the diagnosis and follow-up of haemophilic arthropathy. Haemophilia. 2003;9:76–85
  56. Nuss R, Kilcoyne R. The MRI atlas of hemophilic arthropathy. New York: Professional Publishing Group, Ltd.; 2002;
  57. Gilbert MS. Prophylaxis: musculoskeletal evaluation. Semin Hematol. 1993;30:3–6
  58. Hilliard P, Funk S, Zourikian N, Bergstrom BM, Bradley CS, McLimont M, et al. Hemophilia joint health score reliability study. Haemophilia. 2006;12:518–525
  59. van Genderen FR, van Meeteren NL, van der Bom JG, Heijnen L, de Kleijn P, van den Berg HM, et al. Functional consequences of haemophilia in adults: the development of the Haemophilia Activities List. Haemophilia. 2004;10:565–571
  60. Poonnoose PM, Manigandan C, Thomas R, Shyamkumar NK, Kavitha ML, Bhattacharji S, et al. Functional Independence Score in Haemophilia: a new performance-based instrument to measure disability. Haemophilia. 2005;11:598–602
  61. von Mackensen S, Bullinger M. Development and testing of an instrument to assess the Quality of Life of Children with Haemophilia in Europe (Haemo-QoL). Haemophilia. 2004;10(Suppl 1):17–25
  62. Young NL, Bradley CS, Wakefield CD, Barnard D, Blanchette VS, McCusker PJ. How well does the Canadian Haemophilia Outcomes-Kids’ Life Assessment Tool (CHO-KLAT) measure the quality of life of boys with haemophilia?. Pediatr Blood Cancer. 2006;47:305–311
  63. Bullinger M, von Mackensen S. Quality of life assessment in haemophilia. Haemophilia. 2004;10(Suppl 1):9–16
  64. Bohn RL, Schramm W, Bullinger M, Van den Berg M, Blanchette V. Outcome measures in haemophilia: more than just factor levels. Haemophilia. 2004;10(Suppl 1):2–8
  65. Beeton K, De Kleijn P, Hilliard P, Funk S, Zourikian N, Bergstrom BM, et al. Recent developments in clinimetric instruments. Haemophilia. 2006;12(Suppl 3):102–107
  66. Morado M, Villar A, Jimenez Yuste V, Quintana M, Hernandez Navarro F. Prophylactic treatment effects on inhibitor risk: experience in one centre. Haemophilia. 2005;11:79–83
  67. Santagostino E, Mancuso ME, Rocino A, Mancuso G, Mazzucconi MG, Tagliaferri A, et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol. 2005;130:422–427
  68. Gouw SC, van der Bom JG, van den Berg HM. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood. 2007;109:4648–4654
  69. Valentino LA. FEIBA prophylaxis for patients with haemophilia and inhibitors. Haemophilia. 2006;12(Suppl 5):26–31
  70. Hedner U. Potential role of recombinant factor FVIIa in prophylaxis in severe hemophilia patients with inhibitors. J Thromb Haemost. 2006;4:2498–2500
  71. Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5:1904–1913
  72. Hoots WK, Ebbesen LS, Konkle BA, Auerswald GK, Roberts HR, Weatherall J, et al. Secondary prophylaxis with recombinant activated factor VII improves health-related quality of life of haemophilia patients with inhibitors. Haemophilia. 2008;
  73. Richards M, Altisent C, Batorova A, Chambost H, Dolan G, de Moerloose P, et al. Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data. Haemophilia. 2007;13:473–479
  74. Fischer K, van der Bom JG, Mauser-Bunschoten EP, Roosendaal G, Prejs R, de Kleijn P, et al. The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia. Blood. 2002;99:2337–2341
  75. Fischer K, Van Der Bom JG, Prejs R, Mauser-Bunschoten EP, Roosendaal G, Grobbee DE, et al. Discontinuation of prophylactic therapy in severe haemophilia: incidence and effects on outcome. Haemophilia. 2001;7:544–550
  76. van Dijk K, Fischer K, van der Bom JG, Scheibel E, Ingerslev J, van den Berg HM. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol. 2005;130:107–112
  77. Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia. 2008;14:923–930
  78. Ljung RC. Can haemophilic arthropathy be prevented?. Br J Haematol. 1998;101:215–219
  79. Tagliaferri A, Franchini M, Coppola A, Rivolta GF, Santoro C, Rossetti G, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia. 2008;14:945–951
  80. Schramm W, Royal S, Kroner B, Berntorp E, Giangrande P, Ludlam C, et al. Clinical outcomes and resource utilization associated with haemophilia care in Europe. Haemophilia. 2002;8:33–43
  81. Schramm W, Berger K. Economics of prophylactic treatment. Haemophilia. 2003;9(Suppl 1):111–115[dicussion 6]
  82. Bohn RL, Avorn J. Cost-effectiveness – can it be measured?. Semin Hematol. 1993;30:20–23
  83. Miners AH, Sabin CA, Tolley KH, Lee CA. Cost-utility analysis of primary prophylaxis versus treatment on-demand for individuals with severe haemophilia. Pharmacoeconomics. 2002;20:759–774

PII: S0268-960X(09)00053-8

doi: 10.1016/j.blre.2009.08.001

Blood Reviews
Volume 23, Issue 6 , Pages 267-274 , November 2009

Article Tools

* Image Usage & Resolution